App-Quantinova.ai

MET exon 14 mutation may not be a potential predictive biomarker in Chinese patients.

Si-yang Liu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Deep analysis to inconsistent results of EGFR mutation status in tumor tissues and plasma DNA in advanced NSCLC.

Jie Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Molecular mechanism of transformation from adenocarcinoma to small-cell lung cancer after EGFR-TKI.

Jie-Fei Han - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

N/A

A phase 1b study of famitinib plus docetaxel as 2nd line setting in patients with metastatic non-squamous non-small cell lung cancer and EGFR wild type.

Caicun Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Impact of different MET alterations on the efficacy of crizotinib in non-small-cell lung cancer.

An Na Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Crizotinib

A retrospective analysis of the ICOGEN clinical trial demonstrates the utility of VeriStrat to predict outcome in an all Chinese cohort treated with EGFR TKI.

Yuankai Shi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

VeriStrat

Clinical characteristics associated with metastatic NSCLC harboring ALK rearrangements in Chinese patients.

Guangming Tian - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The radiation sensitization effect of newly discovered EGFR specific inhibitor HS-10182 in human lung cells. - Publication Only: Lung CancerNon-Small Cell Metastatic

Ningbo Liu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Effect of CCR2 antagonism on the metastatic capacity of non-small cell lung cancer cells.

Jun An - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

OrienX010 oncolytic viral therapy in phase a b trial of intralesional injection in unresected stage ac to a acral melanoma patients in China.

Chuanliang Cui - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

OrienX010

A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma (NCT02023710).

Xinan Sheng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mucosal melanoma

Bevacizumab

Association of immune-inflammation index with outcome of high-risk acral melanoma patients treated with adjuvant high-dose interferon.

Jiayi Yu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Interferon

Imatinib versus interferon as adjuvant therapy in a phase II study in patients with highrisk C-Kit mutated melanoma.

Li Li Mao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Interferon

Attitudes of oncology physicians and nurses toward euthanasia and death with dignity.

Hui-ping Chen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

The do-not-resuscitate order for terminal cancer patients in China mainland: A retrospective research.

Boyan Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The awareness of depression and anxiety in cancer patients.

Yu-qing Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Anxiety

N/A

Personal goals among women with breast cancer.

Anu Paul - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Single-center experience with nutrition intervention on patients with advanced colorectal cancer undergoing chemotherapy. - Publication Only: Patient and Survivor Care

Jin-Xiang Lin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Incidence and risk of pneumonitis associated with nivolumab and pembrolizumab in patients with cancer: A meta-analysis of clinical trials.

Ling Peng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pulmonary alveolar proteinosis

Pembrolizumab

Factors correlating with shorter survival after treatment: Aiding oncologists to choose who (not) to receive palliative systemic therapy.

Patty PY Ho - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

24782 Abstracts